Modalis Therapeutics Corporation

Equities

4883

JP3922600006

Biotechnology & Medical Research

Delayed Japan Exchange 08:10:16 2024-03-28 pm EDT 5-day change 1st Jan Change
93 JPY 0.00% Intraday chart for Modalis Therapeutics Corporation -3.12% -25.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Modalis Therapeutics to Reduce Stated Capital and Capital Reserves MT
Japanese Shares Continue to Track Wall Street Higher as Investor Caution Ahead of US Rate Decision Caps Gains MT
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership MT
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement CI
Modalis Therapeutics Corporation announced that it has received ¥505.320864 million in funding from Evolution Capital Management LLC CI
Modalis Therapeutics Corporation announced that it expects to receive ¥505.320864 million in funding from Evolution Capital Management LLC CI
Modalis Therapeutics Corporation cancelled the transaction announced on September 11, 2023 CI
Modalis Therapeutics Corporation announced that it expects to receive ¥18.77952 million in funding from China Silver Asset Management Hong Kong Limited CI
Modalis Therapeutics Corporation to Regain Full Rights to MDL-201 and MDL-202 from Astellas Pharma Inc CI
Modalis Therapeutics Corporation Receives Positive FDA Response for Pre-IND Review for MDL-101 Clinical Development CI
Modalis Therapeutics to Grant Stock Options MT
Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Modalis Therapeutics Corporation to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of A Type of Muscular Dystrophy At the ASGCT Annual Meeting CI
Modalis to Allot Stock Options MT
Modalis Therapeutics to Overcome 2.6 Billion Yen Deficit in Retained Earnings MT
Modalis Therapeutics Corporation Announces Notice of Termination of A Research Collaboration on 205 CI
Modalis Therapeutics Corporation(TSE:4883) dropped from S&P Global BMI Index CI
Modalis Therapeutics Issues Share Acquisition Rights MT
Modalis Therapeutics to Issue Share Acquisition Rights MT
Modalis Therapeutics Swings to Loss in Q1 on Growing Research Costs MT
Modalis Therapeutics Adds Cardiomyopathy Therapy to In-House Pipeline MT
Modalis Therapeutics Corporation Announces Addition of MDL-105 to In-house Pipelines CI
Modalis Therapeutics to Showcase Preclinical Data to American Society of Gene & Cell Therapy MT
Modalis Therapeutics Schedules Issuance of Stock Options; Shares Fall 6% MT
Modalis Therapeutics Schedules Issuance of Stock Options to Directors; Shares Jump 16% MT
Chart Modalis Therapeutics Corporation
More charts
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
More about the company
  1. Stock
  2. Equities
  3. Stock Modalis Therapeutics Corporation - Japan Exchange
  4. News Modalis Therapeutics Corporation
  5. Modalis Therapeutics and Astellas Pharma End Research Collaboration on Nervous System Medication